[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program",
    "summary": "Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially enhancing patient access and affordability. Over the past quarter, Pfizer's share price saw an 11% increase. This move aligns with a broader market upswing, as major indexes achieved record highs. Noteworthy developments during this time included breakthroughs in clinical studies and strategic alliances, which potentially bolstered investor confidence. However, the...",
    "url": "https://finnhub.io/api/news?id=6e7e167424d6a353d4f61db9f070d2a2424252c600a2cba62bcf5ec52d2c5910",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752772888,
      "headline": "Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program",
      "id": 135996912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially enhancing patient access and affordability. Over the past quarter, Pfizer's share price saw an 11% increase. This move aligns with a broader market upswing, as major indexes achieved record highs. Noteworthy developments during this time included breakthroughs in clinical studies and strategic alliances, which potentially bolstered investor confidence. However, the...",
      "url": "https://finnhub.io/api/news?id=6e7e167424d6a353d4f61db9f070d2a2424252c600a2cba62bcf5ec52d2c5910"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: TSMC Lifts 2025 Revenue Growth Guidance; Lucid Partners With Uber on Robotaxi Launch",
    "summary": "All three major US stock indexes were up in late-morning trading Thursday as fresh economic data and",
    "url": "https://finnhub.io/api/news?id=d94db17994f9a835e43ce79d35c3f465634ade5cf28b9e162952cbadd8ccede4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752768222,
      "headline": "Top Midday Stories: TSMC Lifts 2025 Revenue Growth Guidance; Lucid Partners With Uber on Robotaxi Launch",
      "id": 135993315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Thursday as fresh economic data and",
      "url": "https://finnhub.io/api/news?id=d94db17994f9a835e43ce79d35c3f465634ade5cf28b9e162952cbadd8ccede4"
    }
  },
  {
    "ts": null,
    "headline": "Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer",
    "summary": "Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends, market drivers, competitive landscape, and strategies for growth and investment in the NTM market.Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.The report provides an assessmen",
    "url": "https://finnhub.io/api/news?id=9609a74d54c5fbb0bf8e51de11876394f789000defaf570515a6434ca2659f7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752765060,
      "headline": "Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer",
      "id": 135993660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends, market drivers, competitive landscape, and strategies for growth and investment in the NTM market.Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.The report provides an assessmen",
      "url": "https://finnhub.io/api/news?id=9609a74d54c5fbb0bf8e51de11876394f789000defaf570515a6434ca2659f7d"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Zoetis (ZTS) is a Strong Growth Stock",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=6bd7468d9b9351891f6446d4b7d06abc4c0bb2134dfdd7f248e576c0a01ce8e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752759903,
      "headline": "Here's Why Zoetis (ZTS) is a Strong Growth Stock",
      "id": 135993661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=6bd7468d9b9351891f6446d4b7d06abc4c0bb2134dfdd7f248e576c0a01ce8e2"
    }
  },
  {
    "ts": null,
    "headline": "Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility",
    "summary": "WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company’s cell therapy manufacturing operations. This state-of-the-art facility aligns with Tevogen’s strategic goals of accelerating clinical development while mainta",
    "url": "https://finnhub.io/api/news?id=77c4ecd488f146df487db178b86c7ad8611108826f867f2a320f015cbf142612",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752758100,
      "headline": "Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility",
      "id": 135993136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company’s cell therapy manufacturing operations. This state-of-the-art facility aligns with Tevogen’s strategic goals of accelerating clinical development while mainta",
      "url": "https://finnhub.io/api/news?id=77c4ecd488f146df487db178b86c7ad8611108826f867f2a320f015cbf142612"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures",
    "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
    "url": "https://finnhub.io/api/news?id=485fb7fb05e3fd520e3ac282e5629afc9ed54042d70c5ae296ca9aea383cdcd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752757227,
      "headline": "Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures",
      "id": 135993663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
      "url": "https://finnhub.io/api/news?id=485fb7fb05e3fd520e3ac282e5629afc9ed54042d70c5ae296ca9aea383cdcd5"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=8a71c9d5ab86a853221184477543d5cb4cb4f434e36c3abd080016d0691a8630",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752757202,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 135993664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=8a71c9d5ab86a853221184477543d5cb4cb4f434e36c3abd080016d0691a8630"
    }
  },
  {
    "ts": null,
    "headline": "Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector",
    "summary": "Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth potential, and balanced risk profile.",
    "url": "https://finnhub.io/api/news?id=3d3853fa2e7bee6d70f67416c883703b1a0e5c738e0a9923dcf3cb21c8484e08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752751964,
      "headline": "Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector",
      "id": 135992662,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351084382/image_1351084382.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth potential, and balanced risk profile.",
      "url": "https://finnhub.io/api/news?id=3d3853fa2e7bee6d70f67416c883703b1a0e5c738e0a9923dcf3cb21c8484e08"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients",
    "summary": "(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers are under pressure from the Trump administration to lower prices.  The initiative is targeted at the small percentage of patients on Eliquis who are uninsured or underinsured, and health pricing experts cautioned that the discounted price might still be too high for many of those consumers.  The program - which would bypass traditional pharmacy benefit managers and insurers - offers a roughly 43% discount from the list price, cutting the treatment's monthly cost from around $606 to $346.",
    "url": "https://finnhub.io/api/news?id=28d29858840c119eaeb2002ae400ae508470d0b5ed22d1b87f15432d3b227bbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752751278,
      "headline": "Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients",
      "id": 135993665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers are under pressure from the Trump administration to lower prices.  The initiative is targeted at the small percentage of patients on Eliquis who are uninsured or underinsured, and health pricing experts cautioned that the discounted price might still be too high for many of those consumers.  The program - which would bypass traditional pharmacy benefit managers and insurers - offers a roughly 43% discount from the list price, cutting the treatment's monthly cost from around $606 to $346.",
      "url": "https://finnhub.io/api/news?id=28d29858840c119eaeb2002ae400ae508470d0b5ed22d1b87f15432d3b227bbf"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
    "summary": "PRINCETON, N.J., July 17, 2025--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
    "url": "https://finnhub.io/api/news?id=29e625fbe52d72cd32bfc0ccd285f9cfce505a3439f50f85857f0733d6a307ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752749940,
      "headline": "Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
      "id": 135993666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., July 17, 2025--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
      "url": "https://finnhub.io/api/news?id=29e625fbe52d72cd32bfc0ccd285f9cfce505a3439f50f85857f0733d6a307ec"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount",
    "summary": "The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.",
    "url": "https://finnhub.io/api/news?id=fc9a45262e7892e03c8412bf1e51eb5999fcd4d2e0fb991962602f950ff096b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752748200,
      "headline": "Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount",
      "id": 135993667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.",
      "url": "https://finnhub.io/api/news?id=fc9a45262e7892e03c8412bf1e51eb5999fcd4d2e0fb991962602f950ff096b9"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends",
    "summary": "Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends",
    "url": "https://finnhub.io/api/news?id=823f1025d7d68e6a865bf76cb270bcedfe66d9e806b77a16c20a74009e52dd7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752741900,
      "headline": "Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends",
      "id": 135992173,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=823f1025d7d68e6a865bf76cb270bcedfe66d9e806b77a16c20a74009e52dd7b"
    }
  },
  {
    "ts": null,
    "headline": "Thyroid Gland Disorders Diagnostics and Treatment Market Analysis Report 2024-2030 | Incorporation of AI and Advanced Therapeutics Fueling Opportunities",
    "summary": "Global Thyroid Gland Disorders Market Report 2024: Analysis of diagnostics and treatments, revenue projections (2025-2030), and segmentation by disease type, product type, and region. Discover trends, challenges, competitive landscape, ESG developments, and profiles of key players like Amgen and Pfizer. Global Thyroid Gland Disorders Diagnostics and Treatment Market Global Thyroid Gland Disorders Diagnostics and Treatment Market Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Thyroid Gland Disord",
    "url": "https://finnhub.io/api/news?id=aa495739c999699f7c82f6df4be43c48da8ab65021b8e97c7bf7763ec43ce60c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752740280,
      "headline": "Thyroid Gland Disorders Diagnostics and Treatment Market Analysis Report 2024-2030 | Incorporation of AI and Advanced Therapeutics Fueling Opportunities",
      "id": 135993578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Global Thyroid Gland Disorders Market Report 2024: Analysis of diagnostics and treatments, revenue projections (2025-2030), and segmentation by disease type, product type, and region. Discover trends, challenges, competitive landscape, ESG developments, and profiles of key players like Amgen and Pfizer. Global Thyroid Gland Disorders Diagnostics and Treatment Market Global Thyroid Gland Disorders Diagnostics and Treatment Market Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Thyroid Gland Disord",
      "url": "https://finnhub.io/api/news?id=aa495739c999699f7c82f6df4be43c48da8ab65021b8e97c7bf7763ec43ce60c"
    }
  }
]